The purpose of the study is to evaluate the safety and effectiveness of the drug enzomenib, also known as DSP 5336. This medication is an oral tablet that is being tested as a single therapy. During the first part of the study, different doses of the drug will be given to determine the safest and most effective amount for patients. In the second part, the drug will be studied further in specific groups of patients to see how well it works against their particular type of cancer.

The purpose of this study is to find out if bleximenib is safe and effective for treating acute leukemia. In the first phase of the study, researchers will determine the best dose of the medication to use and will check for any side effects. In the second phase, they will test how well the medication works at the recommended dose by measuring whether it can help patients achieve complete remission, which means that signs of the disease are no longer detectable.

The study has different parts. During the dose escalation part, doctors will test different amounts of bleximenib to find the safest and most effective dose. In the dose expansion part, more patients will receive the recommended dose to gather additional information about safety. Throughout the study, participants will be closely monitored for any unwanted effects and to see how their leukemia responds to treatment. The study is open to adults aged 18 years and older, as well as adolescents between 12 and 17 years of age in certain parts of the trial. Participants must have acute leukemia that has come back after previous treatment or has not responded to other therapies, and their leukemia must have specific genetic features that the medication is designed to target.

Participants in the study will be randomly assigned to receive either fosfomycin or ciprofloxacin. Both medications are taken orally, meaning they are swallowed in pill form. The study will monitor the participants over a period of time to see how well each medication works in preventing febrile neutropenia and to ensure the safety of the participants. The goal is to determine if fosfomycin is as effective as ciprofloxacin in preventing infections in these patients.

The study is designed to help improve treatment options for patients with acute leukemia who are at high risk of developing infections due to their weakened immune systems. By comparing these two antibiotics, researchers hope to find the best approach to prevent febrile neutropenia and improve the overall care for patients undergoing chemotherapy or stem cell transplants.

Participants in the study will receive various doses of Revumenib to determine the most effective and safe dose. The study will also look at how the drug is processed in the body, which is known as pharmacokinetics. This includes understanding how the drug is absorbed, distributed, metabolized, and excreted. The study will be conducted in two phases. The first phase will focus on finding the right dose, while the second phase will evaluate the drug’s safety over a longer period and its ability to help patients achieve remission, which means a reduction or disappearance of signs of cancer.

The study will include patients with specific genetic changes in their leukemia, such as the MLL/KMT2A gene rearrangement or Nucleophosmin 1 (NPM1) mutation. These genetic changes can affect how the leukemia behaves and responds to treatment. The trial aims to provide valuable information on the potential benefits and risks of using Revumenib for treating these challenging forms of leukemia. Participants will be closely monitored for any side effects and changes in their health throughout the study.

The study is divided into two phases. In the first phase, the goal is to find the best dose of Ponatinib for children with advanced blood cancers or solid tumors. In the second phase, the study will look at how well Ponatinib works in children with a specific type of leukemia called Chronic Myeloid Leukemia (CML) and other selected cancers. Participants will take Ponatinib orally, which means they will swallow it in the form of a tablet or capsule. The study will monitor the participants’ health and any side effects they may experience while taking the medication.

Throughout the study, researchers will assess the participants’ response to the treatment by using various medical tests and imaging techniques like MRI or CT scans. The study aims to provide valuable information on the potential benefits and risks of using Ponatinib in treating these challenging cancers in children. The study is expected to continue until 2025, allowing researchers to gather comprehensive data on the long-term effects of the treatment.

The purpose of this study is to determine if the combination of Pevonedistat, Venetoclax, and Azacitidine is more effective than the combination of Venetoclax and Azacitidine alone in treating adults with newly diagnosed AML who are not suitable for intensive chemotherapy. Participants in the study will be randomly assigned to one of the two treatment groups. The study will monitor the participants over a period of time to assess the effectiveness and safety of the treatments. The study will also look at how long participants live and how their disease responds to the treatment.

Participants will receive their assigned treatment and will be regularly monitored by healthcare professionals. The study will track various outcomes, including how long it takes for the disease to progress, the overall survival of participants, and the response of the leukemia to the treatment. The study aims to provide valuable information that could improve treatment options for patients with AML who cannot undergo intensive chemotherapy.

Participants in the study will receive either the GnRHa treatment or a placebo, which is a substance with no active medication. The GnRHa treatment being studied is called Pamorelin, which is given as an injection. There are two different doses of Pamorelin being used in the study: 3.75 mg and 11.25 mg. The study will follow participants for several years to monitor their ovarian reserve and other health factors. This includes measuring levels of a hormone called Anti-Müllerian Hormone (AMH), which helps indicate the number of eggs left in the ovaries, at various points after the end of chemotherapy.

Throughout the study, participants will have regular check-ups to assess their ovarian reserve and overall health. This will involve tests like ultrasounds and blood tests to measure hormone levels. The study aims to provide valuable information on how GnRHa might help preserve fertility in young women and teenagers undergoing cancer treatment. By understanding the effects of this treatment, researchers hope to improve future care for patients facing similar challenges.